Board of Directors

Our Board of Directors provides senior advice and guidance to help HOOKIPA achieve its vision and comprises individuals with a broad variety of experience.

Jan van de Winkel

Jan van de Winkel is Chairman of the Board of Directors of HOOKIPA. He is also co-founder of Genmab, having served as President, Research & Development and Chief Scientific Officer (CSO) of the company until his appointment as President and Chief Executive Officer (CEO) in 2010. Prior to Genmab, Jan served as Vice President (VP) and Scientific Director of Medarex Europe. During his 30 years in the therapeutic antibody field, he has authored over 300 scientific publications and has been responsible for more than 100 patents and pending patent applications. Jan is a Professor of Immunotherapy at Utrecht University in The Netherlands. His other roles of seniority include: member of the Board of Directors of LEO Pharma and Omega Alpha SPAC. Jan holds MS and PhD degrees from the University of Nijmegen in The Netherlands.

Michael A. Kelly

Michael A. Kelly is an Independent Director to the Board of Directors of HOOKIPA Pharma. Michael is the Founder & President of Sentry Hill Partners, LLC, a global life sciences transformation and management consulting business and a former senior executive at Amgen, Inc. With more than two decades of global executive leadership in the life sciences industry, Michael A. Kelly was formerly Senior Vice President, Global Business Services and held various strategic finance and commercial operations positions at Amgen, including the role of acting CFO of Amgen, Inc. in 2010 and 2014 and positions at Biogen, Tanox and Monsanto Life Sciences. Throughout his career, Michael has held a variety of strategic finance leadership roles at the Board level, which have successfully led to transformation, restructuring, and integration in environments of rapid innovation and change.
Michael A. Kelly is currently a member of the Board of Directors and serves on the Finance Committee for Direct Relief, a humanitarian aid organization focused on health outcomes and disaster relief.

Michael holds a BSc in business administration from Florida A&M University, concentrating in Finance & Industrial Relations.

David R. Kaufman

David R. Kaufman is a Non-Executive Director of the Board of Directors of HOOKIPA. He currently serves as a Venture Partner at Third Rock Ventures. Prior to joining Third Rock Ventures,
Dr. Kaufman was Chief Medical Officer and Head of Translational Development at The Bill & Melinda Gates Medical Research Institute, and held several leadership positions at Merck Research Laboratories, including Head of Translational Oncology, Executive Director in Clinical Oncology and Associate Director of the Merck Drug Development and Leadership Program.
Dr. Kaufman is a member of the Board of Directors of the Society for Immunotherapy of Cancer (SITC), a not-for-profit medical professional society dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. He holds a Ph.D. in Molecular Virology & Immunology from The Rockefeller University and received his M.D. from Weill Cornell Medical College of Cornell University.
 

Tim Reilly

Tim Reilly is a Non-Executive Director of the Board of Directors of HOOKIPA.  He currently serves as Chief Development Officer at HotSpot Therapeutics, a biotechnology company pioneering the discovery and development of novel small molecule allosteric therapies directed at natural hotspots for the treatment of cancer and autoimmune disease. Prior to taking this role in 2021, Tim spent more than 18 years at Bristol Myers Squibb (BMS). He last served as Senior Vice President within Research & Early Development, where he was responsible for the early development portfolio across therapeutic areas in oncology, immunology, fibrosis, cardiovascular and neuroscience. In this capacity, he oversaw the integration of all nonclinical and clinical efforts, starting from development candidate through Phase 1/2 clinical development. During his time at BMS, he was a contributor to the approval of 12 therapies across a range of diseases, as well as several company acquisitions.  Tim is active in the biotech industry in other capacities; he is a contributor to several biotech companies as an Entrepreneur in Residence through Atlas Ventures, serves as industry representative to the Network Steering Committee of the Experimental Cancer Medicines Centres (ECMC) at Cancer Research UK, and sits on the Translation Research Council for CureSMA. He also is co-founder and Chief Scientific Officer of a non-profit organization, Spinal Muscular Atrophy Research Team (SMART). Tim earned his undergraduate degree from the University of Notre Dame, did his doctoral training in Pharmaceutical Sciences at Wayne State University, and served as a research fellow at the National Institutes of Health.

Julie O´Neill

Julie O’Neill is a Non-Executive Director of the Board of Directors of HOOKIPA. A business professional with more than two decades of executive experience in senior leadership roles, Ms. O’Neill was formerly Executive Vice President, Global Operations at Alexion Pharmaceuticals, Inc. Prior to Alexion, she was Vice President of Operations at Gilead Sciences. Throughout her career in pharmaceutical operations, Ms. O’Neill has held a number of senior roles at the Board and Committee level. She is currently an Independent Director for at ICON plc, DBV Technologies SA, and ILC Dover LLC and is both a Board member and Audit & Risk Committee Chair for the National Institute for Bioprocessing Research & Training (NIBRT). Ms. O’Neill is a Chartered Director and holds a BSc in Pharmacy from Trinity College Dublin and an MBA from University College Dublin.